ADC Therapeutics (ADCT) to Release Earnings on Tuesday

Key Points

• ADC Therapeutics will report Q4 2025 results before the market opens on Tuesday, March 10, 2026, with analysts forecasting ($0.32) EPS and $22.29 million in revenue; a conference call is scheduled for 8:30 AM ET.
• The stock recently traded at $4.04 with a market cap of about $500.9 million, a 52‑week range of $1.05–$4.80, a negative P/E of -2.78 and a beta of 1.92, reflecting notable volatility.
• Analyst sentiment is mixed but leaning positive—MarketBeat shows a consensus of "Moderate Buy" with an average price target of $7.33 (ranging from Guggenheim’s $10 to Weiss’s sell), and institutional investors hold roughly 41.1% after several funds increased stakes.

ADC Therapeutics (NYSE:ADCT - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $22.2920 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:30 AM ET.

ADC Therapeutics Price Performance

NYSE:ADCT traded down $0.20 during trading hours on Thursday, reaching $4.04. 282,810 shares of the company were exchanged, compared to its average volume of 773,335. The firm has a market cap of $500.85 million, a price-to-earnings ratio of -2.78 and a beta of 1.92. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.80. The stock has a 50 day simple moving average of $3.83 and a 200 day simple moving average of $3.83.

Analysts Set New Price Targets

Several research analysts recently weighed in on ADCT shares. Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Wall Street Zen upgraded ADC Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $5.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $7.33.

Institutional Investors Weigh In On ADC Therapeutics

A number of large investors have recently modified their holdings of ADCT. Russell Investments Group Ltd. boosted its holdings in ADC Therapeutics by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 32,502 shares of the company's stock worth $130,000 after acquiring an additional 7,701 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of ADC Therapeutics by 25.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company's stock worth $166,000 after purchasing an additional 9,537 shares in the last quarter. ExodusPoint Capital Management LP boosted its stake in shares of ADC Therapeutics by 23.6% in the fourth quarter. ExodusPoint Capital Management LP now owns 56,783 shares of the company's stock valued at $200,000 after purchasing an additional 10,842 shares during the period. Engineers Gate Manager LP acquired a new stake in ADC Therapeutics during the 4th quarter valued at $43,000. Finally, MetLife Investment Management LLC increased its stake in ADC Therapeutics by 65.3% during the 4th quarter. MetLife Investment Management LLC now owns 49,682 shares of the company's stock worth $175,000 after buying an additional 19,633 shares during the period. Institutional investors and hedge funds own 41.10% of the company's stock.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.